Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting

Patient Preference and Adherence

Volumn 7, Issue , 2013, Pages 391-400

  Celio, Luigi ^a   Ricchini, Francesca ^a   De Braud, Filippo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chemotherapy induced nausea and vomiting; Fosaprepitant; Neurokinin 1 receptor antagonist

Indexed keywords

APREPITANT; CISPLATIN; DEXAMETHASONE; FOSAPREPITANT; GRANISETRON; ONDANSETRON; PALONOSETRON; PLACEBO; SEROTONIN ANTAGONIST; ANTIEMETIC AGENT; CORTICOSTEROID; CYTOCHROME P450 3A4; HISTAMINE H2 RECEPTOR ANTAGONIST; LORAZEPAM; NEUROKININ 1 RECEPTOR; PROTON PUMP INHIBITOR; SEROTONIN 3 ANTAGONIST;

ANOREXIA; AREA UNDER THE CURVE; ASTHENIA; BLOOD TOXICITY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HICCUP; HUMAN; INFECTION; INFUSION RELATED REACTION; META ANALYSIS (TOPIC); MONOTHERAPY; NAUSEA; NEUTROPENIA; OPEN STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TREATMENT DURATION; URINARY TRACT INFECTION; VOMITING; ARTICLE; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG DISTRIBUTION; ERYTHEMA; INJECTION SITE PAIN; MALAISE; OUTCOME ASSESSMENT; PAIN; PATIENT ATTITUDE; PHLEBITIS; PLASMA CONCENTRATION-TIME CURVE; PRURITUS; RISK FACTOR; SWELLING;

EID: 84878031168     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S31288     Document Type: Review

References (53)

1. Cleeland CS, Allen JD, Roberts SA, et al. Reducing the toxicity of cancer therapy: recognizing needs, taking action. Nat Rev Clin Oncol. 2012;9(8):471-478.
2. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358(23):2482-2494.
3. Schwartzberg LS. Chemotherapy-induced nausea and vomiting: clinician and patient perspectives. J Support Oncol. 2007;5(Suppl 1):5-12.
4. Roscoe JA, Morrow GR, Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer. 2011;19(10):1533-1538.
5. Nevidjon B, Chaudhary R. Controlling emesis: evolving challenges, novel strategies. J Support Oncol. 2010;8(Suppl 2):1-10.
6. Trigg ME, Higa GM. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice. J Oncol Pharm Pract. 2010;16(4):233-244.
7. Hesketh PJ, Van Belle S, Aapro M, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer. 2003;39(8):1074-1080.
8. Prommer E. Aprepitant (EMEND): the role of substance P in nausea and vomiting. J Pain Palliat Care Pharmacother. 2005;19(3):31-39.
9. Smith DB, Newlands ES, Rustin GJ, et al. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet. 1991;338(8765):487-490.
10. Hesketh PJ, Harvey WH, Harker WG, et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol. 1994;12(3):596-600.
11. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21(22):4112-4119.
12. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97(12):3090-3098.
13. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23(12):2822-2830.
14. Hargreaves R, Ferreira JC, Hughes D, et al. Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann N Y Acad Sci. 2011;1222:40-48.
15. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189-4198.
16. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(Suppl 5):v232-v243.
17. Bergstrom M, Hargreaves RJ, Burns HD, et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry. 2004;55(10):1007-1012.
18. Huskey SE, Luffer-Atlas D, Dean BJ, McGowan EM, Feeney WP, Chiu SH. Substance P receptor antagonist I: conversion of phosphoramidate prodrug after i.v. administration to rats and dogs. Drug Metab Dispos. 1999;27(11):1367-1373.
19. Sanchez RI, Wang RW, Newton DJ, et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004;32(11):1287-1292.
20. Colon-Gonzales F, Kraft WK. Pharmacokinetic evaluation of fosaprepitant dimeglumine. Expert Opin Drug Metab Toxicol. 2010;6(10): 1277-1286.
21. Lasseter KC, Gambale J, Jin B, et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol. 2007;47(7):834-840.
22. Cocquyt V, Van Belle S, Reinhardt RR, et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer. 2001;37(7):835-842.
23. Van Belle S, Lichinitser MR, Navari RM, et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-754,298 and MK-869: a randomized controlled trial. Cancer. 2002;94(11):3032-3041.
24. Marbury TC, Jin B, Panebianco D, et al. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects. Anesth Analg. 2009;109(2):418-425.
25. dos Santos LV, Souza FH, Brunetto AT, Sasse AD, da Silveira Nogueira Lima JP. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst. 2012;104(17):1280-1292.
26. Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer. 2003;97(9):2290-2300.
27. Majumdar AK, Howard L, Goldberg MR, et al. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol. 2006;46(3):291-300.
28. Grunberg SM, Dugan M, Muss H, et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer. 2009;17(5):589-594.
29. Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer. 2008;112(9):2080-2087.
30. Langford P, Chrisp P. Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting. Core Evid. 2010;5:77-90.
31. Shmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol. 2006;17(6):1000-1006.
32. Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE. J Clin Oncol. 2001;29(11):1495-1501.
33. Saito H, Yoshizawa H, Yoshimori K, et al. Efficacy and safety of a single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial. Ann Oncol. 2013;24(4):1067-1073.
34. Van Laere K, De Hoon J, Bormans G, et al. Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs oral aprepitant as assessed by PET imaging. Clin Pharmacol Ther. 2012;92(2):243-250.
35. Burke TA, Wisniewski T, Ernst FR. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer. 2011;19(1):131-140.
36. Haiderali A, Menditto L, Good M, Teitelbaum A, Wegner J. Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population. Support Care Cancer. 2011;19(6):843-851.
37. Gomez DR, Liao K-P, Giordano S, Nguyen H, Smith BD, Elting LS. Adherence to national guidelines for anti-emesis prophylaxis in patients undergoing chemotherapy for lung cancer. Cancer. 2013;119(7):1428-1436.
38. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59(1):56-66.
39. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004;100(10):2261-2268.
40. Salsman JM, Grunberg SM, Beaumont JL, et al. Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives. J Natl Compr Canc Netw. 2012;10(2): 149-157.
41. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Antiemesis, version 1. 2013. Available from: http://www.nccn.org/professional/physician_gls/PDF/antiemesis.pdf. Accessed February 8, 2013.
42. Grunberg S, Ettinger DS, Hauber AB, et al. How familiar are oncologists with therapeutic care and supportive care guidelines [abstract]? Support Care Cancer. 2008;16:631-632.
43. Aapro M, Molassiotis A, Dicato M, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol. 2012;23(8):1986-1992.
44. Chan A, Low XH, Yap KY. Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy. J Manag Care Pharm. 2012;18(5):385-394.
45. Celio L, Agustoni F, Testa I, Dotti K, De Braud F. Palonosetron: an evidence-base choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Tumori. 2012;98(3):279-286.
46. Celio L, Frustaci S, Denaro A, et al. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer. 2011;19(8):1217-1225.
47. Aapro M, Fabi A, Nolè F, et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol. 2010;21(5):1083-1088.
48. Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med. 2011;364(21):2060-2065.
49. Basch E, Somerfield MR, Partridge A, Schnipper L, Lyman GH. Commentary: Should cost and comparative value of treatments be considered in clinical practice guidelines? J Oncol Pract. 2011;7(6): 398-401.
50. Tina Shih Y-C, Ying X, Elting LS. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer. 2007;110(3):678-685.
51. Lordick F, Ehlken B, Ihbe-Heffinger A, et al. Health outcomes and cost-effectiveness of aprepitant in outpatient receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer. 2007;43(2):299-307.
52. Annemans L, Strens D, Lox E, Petit C, Malonne H. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. Support Care Cancer. 2008;16(8): 905-915.
53. Moore S, Tumeh J, Wojtanowski S, Flowers C. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Value Health. 2007;10(1):23-31.